SIGA Technologies - Momentum building as the year progresses
SIGA Technologies had another strong quarter in Q224, driven by intravenous TPOXX (IVT) deliveries to the Strategic National Stockpile (SNS) and incremental international orders for oral TPOXX. Product revenues of $20.7m (not including the $1.1m R&D income) improved materially from $1.3m in Q223 and comprised $17.6m from IVT sales and $3.1m from international deliveries (including $2.7m under the ASEAN deal). BARDA exercising the remaining $112.5m oral TPOXX option means that top-line momentum will continue into H224. SIGA’s cash position is healthy (post-dividend net cash $107m, no debt) and we expect it to improve further with the upcoming BARDA deliveries (from Q424). We tweak our estimates slightly to reflect the possible timing differences in deliveries and our valuation adjusts from $16.01/share to $15.89/share.SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.